Gnomestar Craft Past Earnings Performance
Past criteria checks 0/6
Gnomestar Craft has been growing earnings at an average annual rate of 34%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been declining at an average rate of 49.9% per year.
Key information
34.0%
Earnings growth rate
37.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -49.9% |
| Return on equity | n/a |
| Net Margin | -566.3% |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gnomestar Craft makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 0 | -1 | 0 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -3 | 1 | 0 |
| 30 Sep 19 | 0 | -4 | 2 | 0 |
| 30 Jun 19 | 0 | -4 | 2 | 0 |
| 31 Mar 19 | 0 | -4 | 2 | 0 |
| 31 Dec 18 | 0 | -3 | 2 | 0 |
| 30 Sep 18 | 0 | -3 | 2 | 0 |
| 30 Jun 18 | 0 | -3 | 2 | 0 |
| 31 Mar 18 | 0 | -4 | 3 | 0 |
| 31 Dec 17 | 0 | -4 | 3 | 0 |
| 30 Sep 17 | 0 | -8 | 4 | 0 |
| 30 Jun 17 | 0 | -7 | 4 | 0 |
| 31 Mar 17 | 0 | -6 | 3 | 0 |
| 31 Dec 16 | 0 | -6 | 3 | 0 |
| 30 Sep 16 | 0 | -2 | 1 | 0 |
| 30 Jun 16 | 0 | -3 | 2 | 0 |
| 31 Mar 16 | 0 | -2 | 2 | 0 |
Quality Earnings: GNOM is currently unprofitable.
Growing Profit Margin: GNOM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GNOM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GNOM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GNOM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: GNOM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.